IDN-7314 是一种泛 Caspase 抑制剂,对所有受试 Caspase 的 IC50 为 0.2-7 nM,可消除 Jo2 诱导的 caspase-3/7 活性,降低肝细胞组织因子促凝血活性,并可用于化学诱导性肝炎、暴发性肝衰竭以及凋亡性肝损伤的相关研究。
产品编号: MS-F28625 CAS No.: 254750-11-3 分子式: C22H17F6N3O7 分子量: 549.38
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

IDN-7314 是一种泛 Caspase 抑制剂,对所有受试 Caspase 的 IC50 为 0.2-7 nM,可消除 Jo2 诱导的 caspase-3/7 活性,降低肝细胞组织因子促凝血活性,并可用于化学诱导性肝炎、暴发性肝衰竭以及凋亡性肝损伤的相关研究。

生物实验数据

生物活性 IDN-7314 is a pan-caspase inhibitor with an IC50 of 0.2-7 nM against all caspases tested, which eliminates Jo2-induced caspase-3/7 activity, reduces hepatocyte tissue factor procoagulant activity, and can be used in studies related to chemically induced hepatitis, fulminant hepatic failure, and apoptotic liver injury.
IC50 & Target

Caspase 3

 

Caspase-7

 

体外研究
(In Vitro)

IDN-7314 是一种强效的泛半胱天冬酶抑制剂,对所有受试半胱天冬酶的 IC50 值为 0.2-7 nM。
IDN-7314 (100 nM) 可完全消除 Jo2 诱导的 caspase-3/7 活性,并显著降低肝细胞组织因子促凝血活性及组织因子阳性微囊泡的释放。

体内研究
(In Vivo)

IDN-7314 (10 mg/kg;腹腔注射) 可强效抑制半乳糖胺诱导的雌性 Sprague-Dawley 大鼠肝细胞凋亡与 caspase-3 活化,根据给药方案的不同,可使凋亡肝细胞减少 76%-71%,但在该模型中仅能轻度降低血浆 ALT 水平与胀亡细胞死亡。
IDN-7314 (腹腔注射;单剂量,3 mg/kg) 可抑制 caspase 活化、阻止促凝血改变,并减轻 Fas 诱导的凋亡性肝损伤小鼠的肝细胞损伤。

Animal Model: Sprague-Dawley (female, 150-200 g, chemical-induced hepatitis model)
Dosage: 10 mg/kg (6-hour observation group); 10 mg/kg (24-hour two-dose group); 10 mg/kg (24-hour pretreatment group)
Administration: i.p.; two doses at 3 and 4.5 hours post-galactosamine (6-hour group); two doses at 3 and 6 hours post-galactosamine (24-hour two-dose group); three doses 30 minutes pre-galactosamine, 3 and 6 hours post-galactosamine (24-hour pretreatment group)
Result: Reduced the percentage of apoptotic hepatocytes by 76% (from 5.0 ± 0.34% to baseline-like levels) at 6 hours post-galactosamine.
Reduced hepatic and plasma caspase-3 activities to control levels at 6 hours post-galactosamine.
Prevented procaspase-3 processing to its active fragment at 6 hours post-galactosamine.
Did not reduce plasma ALT activities at 6 hours post-galactosamine.
Had no significant effect on oncotic cell counts at 6 hours post-galactosamine.
Reduced plasma ALT levels by 57% (p < 0.05) at 24 hours post-galactosamine (two-dose schedule).
Reduced hepatocellular oncosis by 24% (p > 0.05) at 24 hours post-galactosamine (two-dose schedule).
Reduced hepatic and plasma caspase-3 activities to baseline at 24 hours post-galactosamine (two-dose schedule).
Reduced the percentage of apoptotic hepatocytes by 71% (from 7.3 ± 1.1% to 2.1 ± 0.4%) at 24 hours post-galactosamine (three-dose pretreatment schedule).
Had no significant effect on plasma ALT activities or oncotic cell counts at 24 hours post-galactosamine (three-dose pretreatment schedule).
Animal Model: Sprague-Dawley (female, 150-200 g, chemical-induced hepatitis model)
Dosage: 10 mg/kg
Administration: i.p.; two doses at 3 and 4.5 hours post-galactosamine/endotoxin injection
Result: Reduced hepatic caspase-3 activities from 194 ± 33 ΔF/min/mg protein to baseline 16 ± 5 ΔF/min/mg protein.
Reduced plasma caspase-3 activities from 12.9 ± 1.5 ΔF/min/mg protein to baseline 0.2 ± 0.2 ΔF/min/mg protein.
Reduced the percentage of apoptotic hepatocytes by 80% (from 7.33 ± 0.32% to 1.50 ± 0.29%).
Reduced plasma ALT activities by 50% (from 708 ± 54 IU/L to 359 ± 34 IU/L).
Reduced the percentage of oncotic hepatocytes by 33% (from 2.35 ± 0.22% to 1.58 ± 0.13%).
Animal Model: C57BL/6J (male, 8-12 weeks old, Fas-induced apoptotic liver injury model)
Dosage: 3 mg/kg
Administration: i.p.; single dose (administered 1 hour after Jo2 injection)
Result: Attenuated Jo2-induced hepatic cleaved caspase-3 levels.
Abolished Jo2-induced increases in plasma alanine aminotransferase (ALT) activity.
Eliminated Jo2-induced hepatic sinusoidal congestion/hemorrhage.
Completely prevented Jo2-induced increases in plasma TF-positive microvesicle levels.
Blocked Jo2-induced increases in plasma thrombin-antithrombin (TAT) levels.
Attenuated Jo2-induced hepatic fibrin(ogen) β chain accumulation.
Abolished Jo2-induced hepatic cleaved caspase-3 staining and dramatically reduced hepatic fibrin(ogen) deposition.

化学信息

分子量 549.38
分子式 C22H17F6N3O7
CAS No. 254750-11-3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础